Project description
An enhanced diagnostic tool identifying numerous diseases will soon be more accessible
DNA and RNA are so well-known they have practically become the topic of cocktail conversation. The new kids on the block are microRNAs (miRNAs). Since their serendipitous discovery in the early 1990s, there are now over 2 000 known miRNAs in humans believed to regulate about a third of the genes in the genome. These small pieces of RNA, about 25 nucleotides in length, regulate critical cellular functions including development, differentiation, growth and metabolism. Conditions as diverse as cancer, liver disease and age-related conditions have all been linked to miRNA function gone awry. LIVELMIA is developing a plan to get its miRNA analysis technology to market. Faster and cheaper diagnostic technology will encourage widespread uptake in clinics and hospitals globally.
Objective
MicroRNAs (miRNAs) are a class of newly discovered biomolecules implicated in numerous biological systems and in common human diseases (e.g. cancer, Alzheimer, osteoarthritis). It has been shown that MiRNAs are biomarkers with great diagnostic and prognostic value. MiRNAs can be the next generation targets for diagnostics and therapeutics and this is reflected in the miRNA analysis market which is forecasted to have a CAGR of 23.4% in the coming years. Unfortunately, miRNAs are very difficult to detect and measure. The methods we have today are complex, expensive and time consuming. These limitations are restricting the use of miRNA in clinics and hospitals for diagnostic medicine.
LIVELMIA is an answer to these problems. We has succeeded in developing a disruptive innovative method for high-throughput miRNAs analyses, that allows a general improvement in terms of cost, easy-of-use and accuracy. We have cut down the time required by nearly a factor of 2, bringing the total analysis time down from 6 hours to 3 hours. Furthermore LIVELMIA has a high specificity making it ideal in diagnostics to ensure quality readings in any condition. LIVELMIA is a chemical assay kit for quantification of miRNAs on various types of samples (blood, biopsies, cells) with applications in the field of health research and diagnostics medicine. Our ultimate goal is helping biomedical researchers to improve miRNA studies and move miRNA analysis from laboratory to the clinic to bring profound benefits to public health.
Today we have a TRL6/7 prototype. We are gaining considerable interest from potential customers, dealers and stakeholders. We have filed for a patent in 2018 and we are now submitting this Phase 1 proposal in order to study the feasibility and develop a business plan for LIVELMIA, where we intend to study the best segments for exploitation, our pricing strategy, costs, etc.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health
- medical and health sciences basic medicine neurology dementia alzheimer
- natural sciences biological sciences biochemistry biomolecules
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
40124 Bologna
Italy
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.